During the past decade, Midwest Eye Institute conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 18 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 11 clinical trials were completed. i.e. 122.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Midwest Eye Institute" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Apellis Pharmaceuticals, Inc." with 4 trials sponsored, "Clearside Biomedical, Inc." with 4 trials sponsored, "Gyroscope Therapeutics Limited" with 4 trials sponsored and "Genaera Corporation" with 4 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Midwest Eye Institute" #1 collaborator was "Novartis Pharmaceuticals" with 4 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Duke University" with 1 trials as a collaborator and "Juvenile Diabetes Research Foundation" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Midwest Eye Institute" are "Geographic Atrophy" (9 trials), "Diabetic Macular Edema" (8 trials), "Macular Degeneration" (7 trials), "Dry Age-related Macular Degeneration" (5 trials) and "Panuveitis" (5 trials). Many other conditions were trialed in "Midwest Eye Institute" in a lesser frequency.

Most popular intervention types in "Midwest Eye Institute" are "Drug" (43 trials), "Other" (7 trials), "Biological" (4 trials), "Procedure" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (8 trials), "Faricimab" (5 trials), "Placebo" (5 trials), "Ranibizumab" (5 trials) and "Sham" (3 trials). Other intervention names were less common.

The vast majority of trials in "Midwest Eye Institute" are 47 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Midwest Eye Institute". undefined are not yet recruiting, 1 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in Midwest Eye Institute, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Midwest Eye Institute, 8 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".